Fig. 5From: Effect of the versatile bifunctional chelator AAZTA5 on the radiometal labelling properties and the in vitro performance of a gastrin releasing peptide receptor antagonistIn vitro therapy assessing the effect of monotherapy (rapamycin or 177Lu-labelled LF1) and combination therapy (rapamycin and 177Lu-laballed LF1) on PC3 cellsBack to article page